Teladoc Health, Inc.TDOCNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank51
5Y CAGR-50.9%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-50.9%/yr
Long-term compound
Percentile
P51
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 5.97% |
| Q3 2025 | -40.24% |
| Q2 2025 | 61.63% |
| Q1 2025 | 237.95% |
| Q4 2024 | -80.87% |
| Q3 2024 | 0.64% |
| Q2 2024 | 32.10% |
| Q1 2024 | 163.03% |
| Q4 2023 | -71.06% |
| Q3 2023 | 22.48% |
| Q2 2023 | 0.37% |
| Q1 2023 | 4.89% |
| Q4 2022 | -1.96% |
| Q3 2022 | 7.49% |
| Q2 2022 | -9.97% |
| Q1 2022 | 19.96% |
| Q4 2021 | -9.20% |
| Q3 2021 | -0.63% |
| Q2 2021 | 3.53% |
| Q1 2021 | -15.85% |
| Q4 2020 | 209.42% |
| Q3 2020 | 30.09% |
| Q2 2020 | 19.59% |
| Q1 2020 | 18.53% |
| Q4 2019 | 3.18% |
| Q3 2019 | -5.51% |
| Q2 2019 | 4.24% |
| Q1 2019 | 18.04% |
| Q4 2018 | -0.24% |
| Q3 2018 | -5.37% |
| Q2 2018 | 11.19% |
| Q1 2018 | 23.53% |
| Q4 2017 | 4.84% |
| Q3 2017 | 32.20% |
| Q2 2017 | 15.74% |
| Q1 2017 | 10.49% |
| Q4 2016 | 0.46% |
| Q3 2016 | 21.50% |
| Q2 2016 | -7.58% |
| Q1 2016 | 25.60% |